Literature DB >> 26190651

2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.

Xudong Fu1, Randall M Chin2, Laurent Vergnes3, Heejun Hwang1, Gang Deng4, Yanpeng Xing4, Melody Y Pai2, Sichen Li5, Lisa Ta1, Farbod Fazlollahi6, Chuo Chen7, Robert M Prins8, Michael A Teitell9, David A Nathanson1, Albert Lai5, Kym F Faull6, Meisheng Jiang1, Steven G Clarke10, Timothy F Cloughesy11, Thomas G Graeber12, Daniel Braas13, Heather R Christofk14, Michael E Jung15, Karen Reue16, Jing Huang17.   

Abstract

We discovered recently that the central metabolite α-ketoglutarate (α-KG) extends the lifespan of C. elegans through inhibition of ATP synthase and TOR signaling. Here we find, unexpectedly, that (R)-2-hydroxyglutarate ((R)-2HG), an oncometabolite that interferes with various α-KG-mediated processes, similarly extends worm lifespan. (R)-2HG accumulates in human cancers carrying neomorphic mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes. We show that, like α-KG, both (R)-2HG and (S)-2HG bind and inhibit ATP synthase and inhibit mTOR signaling. These effects are mirrored in IDH1 mutant cells, suggesting a growth-suppressive function of (R)-2HG. Consistently, inhibition of ATP synthase by 2-HG or α-KG in glioblastoma cells is sufficient for growth arrest and tumor cell killing under conditions of glucose limitation, e.g., when ketone bodies (instead of glucose) are supplied for energy. These findings inform therapeutic strategies and open avenues for investigating the roles of 2-HG and metabolites in biology and disease.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26190651      PMCID: PMC4663076          DOI: 10.1016/j.cmet.2015.06.009

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  37 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Mammalian TOR: a homeostatic ATP sensor.

Authors:  P B Dennis; A Jaeschke; M Saitoh; B Fowler; S C Kozma; G Thomas
Journal:  Science       Date:  2001-11-02       Impact factor: 47.728

3.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

4.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

5.  NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d-2-hydroxyglutaric aciduria.

Authors:  Stefan Kölker; Verena Pawlak; Barbara Ahlemeyer; Jürgen G Okun; Friederike Hörster; Ertan Mayatepek; Josef Krieglstein; Georg F Hoffmann; Georg Köhr
Journal:  Eur J Neurosci       Date:  2002-07       Impact factor: 3.386

6.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.

Authors:  Zachary J Reitman; Genglin Jin; Edward D Karoly; Ivan Spasojevic; Jian Yang; Kenneth W Kinzler; Yiping He; Darell D Bigner; Bert Vogelstein; Hai Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-02       Impact factor: 12.779

7.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

8.  IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

Authors:  Martin J van den Bent; Hendrikus J Dubbink; Yannick Marie; Alba A Brandes; Martin J B Taphoorn; Pieter Wesseling; Marc Frenay; Cees C Tijssen; Denis Lacombe; Ahmed Idbaih; Ronald van Marion; Johan M Kros; Winand N M Dinjens; Thierry Gorlia; Marc Sanson
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 13.801

9.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

10.  Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.

Authors:  Fang Wang; Jeremy Travins; Byron DeLaBarre; Virginie Penard-Lacronique; Stefanie Schalm; Erica Hansen; Kimberly Straley; Andrew Kernytsky; Wei Liu; Camelia Gliser; Hua Yang; Stefan Gross; Erin Artin; Veronique Saada; Elena Mylonas; Cyril Quivoron; Janeta Popovici-Muller; Jeffrey O Saunders; Francesco G Salituro; Shunqi Yan; Stuart Murray; Wentao Wei; Yi Gao; Lenny Dang; Marion Dorsch; Sam Agresta; David P Schenkein; Scott A Biller; Shinsan M Su; Stephane de Botton; Katharine E Yen
Journal:  Science       Date:  2013-04-04       Impact factor: 63.714

View more
  99 in total

1.  Novel IDH1-Targeted Glioma Therapies.

Authors:  Georg Karpel-Massler; Trang T T Nguyen; Enyuan Shang; Markus D Siegelin
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

2.  One mutation, three phenotypes: novel metabolic insights on MELAS, MIDD and myopathy caused by the m.3243A > G mutation.

Authors:  Karien Esterhuizen; J Zander Lindeque; Shayne Mason; Francois H van der Westhuizen; Richard J Rodenburg; Paul de Laat; Jan A M Smeitink; Mirian C H Janssen; Roan Louw
Journal:  Metabolomics       Date:  2021-01-12       Impact factor: 4.290

3.  Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice.

Authors:  Rongying Ou; Jia Liu; Mingfen Lv; Jingying Wang; Jinmeng Wang; Li Zhu; Liang Zhao; Yunsheng Xu
Journal:  Endocrine       Date:  2017-04-06       Impact factor: 3.633

Review 4.  Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma.

Authors:  Peter M Clark; Wilson X Mai; Timothy F Cloughesy; David A Nathanson
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

Review 5.  Emerging applications of metabolomics in drug discovery and precision medicine.

Authors:  David S Wishart
Journal:  Nat Rev Drug Discov       Date:  2016-03-11       Impact factor: 84.694

Review 6.  Metabolite sensing and signaling in cancer.

Authors:  Yi-Ping Wang; Jin-Tao Li; Jia Qu; Miao Yin; Qun-Ying Lei
Journal:  J Biol Chem       Date:  2020-07-07       Impact factor: 5.157

7.  Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma.

Authors:  Tao Wang; Esther Drill; Efsevia Vakiani; Linda Ma Pak; Thomas Boerner; Gokce Askan; Juan Manuel Schvartzman; Amber L Simpson; William R Jarnagin; Carlie S Sigel
Journal:  Hum Pathol       Date:  2019-05-21       Impact factor: 3.466

Review 8.  Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.

Authors:  Claudio Vernieri; Stefano Casola; Marco Foiani; Filippo Pietrantonio; Filippo de Braud; Valter Longo
Journal:  Cancer Discov       Date:  2016-11-21       Impact factor: 39.397

9.  L2hgdh Deficiency Accumulates l-2-Hydroxyglutarate with Progressive Leukoencephalopathy and Neurodegeneration.

Authors:  Shenghong Ma; Renqiang Sun; Bowen Jiang; Jun Gao; Wanglong Deng; Peng Liu; Ruoyu He; Jing Cui; Minbiao Ji; Wei Yi; Pengyuan Yang; Xiaohui Wu; Yue Xiong; Zilong Qiu; Dan Ye; Kun-Liang Guan
Journal:  Mol Cell Biol       Date:  2017-03-31       Impact factor: 4.272

10.  Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma.

Authors:  Yiru Zhang; Chiaki Tsuge Ishida; Wataru Ishida; Sheng-Fu L Lo; Junfei Zhao; Chang Shu; Elena Bianchetti; Giulio Kleiner; Maria J Sanchez-Quintero; Catarina M Quinzii; Mike-Andrew Westhoff; Georg Karpel-Massler; Peter Canoll; Markus D Siegelin
Journal:  Clin Cancer Res       Date:  2018-05-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.